TY - JOUR T1 - Evidence for structural protein damage and membrane lipid remodeling in red blood cells from COVID-19 patients JF - medRxiv DO - 10.1101/2020.06.29.20142703 SP - 2020.06.29.20142703 AU - Tiffany Thomas AU - Davide Stefanoni AU - Monika Dzieciatkowska AU - Aaron Issaian AU - Travis Nemkov AU - Ryan C. Hill AU - Richard O Francis AU - Krystalyn E. Hudson AU - Paul W. Buehler AU - James C. Zimring AU - Eldad A. Hod AU - Kirk C. Hansen AU - Steven L. Spitalnik AU - Angelo D’Alessandro Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/30/2020.06.29.20142703.abstract N2 - The SARS-CoV-2 beta coronavirus is the etiological driver of COVID-19 disease, which is primarily characterized by shortness of breath, persistent dry cough, and fever. Because they transport oxygen, red blood cells (RBCs) may play a role in the severity of hypoxemia in COVID-19 patients.The present study combines state-of-the-art metabolomics, proteomics, and lipidomics approaches to investigate the impact of COVID-19 on RBCs from 23 healthy subjects and 29 molecularly-diagnosed COVID-19 patients. RBCs from COVID-19 patients had increased levels of glycolytic intermediates, accompanied by oxidation and fragmentation of ankyrin, spectrin beta, and the N-terminal cytosolic domain of band 3 (AE1). Significantly altered lipid metabolism was also observed, especially short and medium chain saturated fatty acids, acyl-carnitines, and sphingolipids. Nonetheless, there were no alterations of clinical hematological parameters, such as RBC count, hematocrit, and mean corpuscular hemoglobin concentration, with only minor increases in mean corpuscular volume. Taken together, these results suggest a significant impact of SARS-CoV-2 infection on RBC structural membrane homeostasis at the protein and lipid levels. Increases in RBC glycolytic metabolites are consistent with a theoretically improved capacity of hemoglobin to off-load oxygen as a function of allosteric modulation by high-energy phosphate compounds, perhaps to counteract COVID-19-induced hypoxia. Conversely, because the N-terminus of AE1 stabilizes deoxyhemoglobin and finely tunes oxygen off-loading, RBCs from COVID-19 patients may be incapable of responding to environmental variations in hemoglobin oxygen saturation when traveling from the lungs to peripheral capillaries and, as such, may have a compromised capacity to transport and deliver oxygen.Key PointsCOVID-19 promotes oxidation and fragmentation of membrane proteins, including the N-term of band 3RBCs from COVID-19 patients are characterized by increases in glycolysis and altered lipidomesCOVID-19 impacts two critical mechanisms that finely tune red cell membranes and hemoglobin oxygen affinityCompeting Interest StatementThough unrelated to the contents of this manuscript, the authors declare that AD, KCH, and TN are founders of Omix Technologies Inc and Altis Biosciences LLC. AD and SLS are consultants for Hemanext Inc. SLS is also a consultant for Tioma, Inc. JCZ is a consultant for Rubius Therapeutics. All the other authors disclose no conflicts of interest relevant to this study.Funding StatementThis research was supported by funds from the Boettcher Webb-Waring Investigator Award (ADA), RM1GM131968 (ADA and KCH) from the National Institute of General and Medical Sciences, and R01HL146442 (ADA), R01HL149714 (ADA), R01HL148151 (ADA, SLS, JCZ), R21HL150032 (ADA), and T32 HL007171 (TN) from the National Heart, Lung, and Blood Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This observational study was conducted according to the Declaration of Helsinki, in accordance with good clinical practice guidelines, and approved by the Columbia University Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the raw data for this manuscript are provided in Supplementary Table 1 ER -